Jiangsu Hengrui Medicine
600276.SS
#505
Rank
ยฃ32.15 B
Marketcap
ยฃ5.04
Share price
0.30%
Change (1 day)
-0.67%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Revenue for Jiangsu Hengrui Medicine (600276.SS)

Revenue in 2024 (TTM): ยฃ2.83 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current revenue (TTM ) is ยฃ2.86 Billion. In 2023 the company made a revenue of ยฃ2.52 Billion a decrease over the revenue in the year 2022 that were of ยฃ2.60 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Jiangsu Hengrui Medicine from 2002 to 2024

Annual revenue

Year Revenue Change
2024 (TTM) ยฃ2.83 B12.06%
2023 ยฃ2.52 B-2.87%
2022 ยฃ2.60 B-12.25%
2021 ยฃ2.96 B-0.46%
2020 ยฃ2.97 B16.37%
2019 ยฃ2.55 B24.57%
2018 ยฃ2.05 B34.4%
2017 ยฃ1.52 B13.48%
2016 ยฃ1.34 B35.27%
2015 ยฃ0.99 B28.69%
2014 ยฃ0.77 B26.03%
2013 ยฃ0.61 B14.88%
2012 ยฃ0.53 B17.14%
2011 ยฃ0.45 B26.42%
2010 ยฃ0.36 B31.59%
2009 ยฃ0.27 B15.49%
2008 ยฃ0.23 B80.7%
2007 ยฃ0.13 B42.69%
2006 ยฃ92.11 M10%
2005 ยฃ83.73 M20.92%
2004 ยฃ69.25 M-2.47%
2003 ยฃ71 M24.61%
2002 ยฃ56.98 M